<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905189</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A01612-41</org_study_id>
    <nct_id>NCT01905189</nct_id>
  </id_info>
  <brief_title>Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension</brief_title>
  <acronym>RETRIEVE</acronym>
  <official_title>Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary arterial hypertension is a disease characterised by pathological changes in the
      pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and
      pulmonary artery pressure. Right ventricular failure is the main cause of death in patients
      with pulmonary arterial hypertension, and the ability of the right ventricle to adapt to the
      progressive increase in pulmonary vascular resistance associated with changes to the
      pulmonary vasculature in pulmonary arterial hypertension is the main determinant of a
      patient's functional capacity and survival.

      Right ventricular dyssynchrony was present in a substantial proportion of patients with
      pulmonary arterial hypertension and this dyssynchrony adversely affected right ventricular
      function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac index measured during right catheterization</measure>
    <time_frame>After two minutes of right stimulation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Hemodynamic study, cardiac pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resynchronization therapy of right ventricle</intervention_name>
    <description>Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy</description>
    <arm_group_label>Hemodynamic study, cardiac pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary hypertension type I, III, IV, V Dana Point classification

          -  NYHA classification equal or superior to stage II

          -  During right catetherization : cardiac index inferior or equal 2.5 L/mn/m2 and atrial
             pressure superior or equal 10 mmHg OR cardiac index equal or inferior to 2.2 L/mn/m2

          -  Optimal therapy considered by the referring specialist practioner of the patient

        Exclusion Criteria:

          -  Minor or incapacitated adult

          -  Pregnancy

          -  Unability to give free and informed consent

          -  Pulmonary hypertension type II Dana Point classification

          -  Eisenmenger syndrome

          -  Patent foramen ovale

          -  Left bundle-brach block

          -  Pulmonary hypertension exacerbation

          -  Medical clinical situation considered inappropriate by the investigator

          -  Patient eligible for a heart-lung transplant

          -  Patient eligible for pulmonary endarterectomy

          -  Patient with poor echogenicity

          -  Filter in the inferior vena cava
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul-Ursmar Milliez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caen UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul-Ursmar Milliez, MD, PhD</last_name>
    <phone>+33231065118</phone>
    <email>milliez-p@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen UH</name>
      <address>
        <city>Caen</city>
        <state>Basse-Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul-Ursmar Milliez</last_name>
      <phone>+33231065118</phone>
      <email>milliez-p@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Arnaud Pellissier</last_name>
      <phone>+33231065118</phone>
      <email>pellissier-a@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arnaud Pellissier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Ursmar Milliez</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Gomes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Bergot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farzin Beygui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien Labombarda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Lebon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Roule</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RÃ©mi Sabatier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Saloux</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice Scanu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Champ-Rigot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>cardiac resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

